DK0920873T3 - Stabiliserede teriparatidoplösninger - Google Patents

Stabiliserede teriparatidoplösninger

Info

Publication number
DK0920873T3
DK0920873T3 DK98123225T DK98123225T DK0920873T3 DK 0920873 T3 DK0920873 T3 DK 0920873T3 DK 98123225 T DK98123225 T DK 98123225T DK 98123225 T DK98123225 T DK 98123225T DK 0920873 T3 DK0920873 T3 DK 0920873T3
Authority
DK
Denmark
Prior art keywords
stabilized teriparatide
solutions
teriparatide solutions
stabilized
teriparatide
Prior art date
Application number
DK98123225T
Other languages
English (en)
Inventor
Chin-Ming Chang
Henry A Havel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22086574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0920873(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0920873T3 publication Critical patent/DK0920873T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
DK98123225T 1997-12-09 1998-12-07 Stabiliserede teriparatidoplösninger DK0920873T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6907597P 1997-12-09 1997-12-09

Publications (1)

Publication Number Publication Date
DK0920873T3 true DK0920873T3 (da) 2004-06-28

Family

ID=22086574

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03104219.5T DK1417972T4 (da) 1997-12-09 1998-12-07 Stabiliserede teriparatid-opløsninger
DK98123225T DK0920873T3 (da) 1997-12-09 1998-12-07 Stabiliserede teriparatidoplösninger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03104219.5T DK1417972T4 (da) 1997-12-09 1998-12-07 Stabiliserede teriparatid-opløsninger

Country Status (31)

Country Link
EP (2) EP0920873B1 (da)
JP (1) JP4405666B2 (da)
KR (1) KR100482703B1 (da)
CN (1) CN1198644C (da)
AR (1) AR018526A1 (da)
AT (1) ATE260113T1 (da)
AU (1) AU759726B2 (da)
BR (1) BR9813463A (da)
CA (1) CA2314313C (da)
CY (1) CY1114000T1 (da)
CZ (1) CZ302401B6 (da)
DE (1) DE69821872T2 (da)
DK (2) DK1417972T4 (da)
EA (1) EA004761B1 (da)
EG (1) EG23675A (da)
ES (2) ES2215268T3 (da)
HU (1) HU230784B1 (da)
ID (1) ID27741A (da)
IL (1) IL136662A (da)
MY (1) MY120063A (da)
NO (1) NO327302B1 (da)
NZ (1) NZ505222A (da)
PE (1) PE20000001A1 (da)
PL (1) PL194268B1 (da)
PT (2) PT920873E (da)
SK (1) SK288203B6 (da)
TR (1) TR200002134T2 (da)
TW (1) TW570811B (da)
UA (1) UA72884C2 (da)
WO (1) WO1999029337A1 (da)
ZA (1) ZA9811127B (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
CA2335340C (en) * 1998-07-23 2013-03-05 Eli Lilly And Company Fsh and fsh variant formulations, products and methods
AR033639A1 (es) 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
EP1301200A2 (en) * 2000-05-19 2003-04-16 Bionebraska, Inc. Peptide pharmaceutical formulations
BR0112381A (pt) * 2000-06-30 2003-05-06 Suntory Ltd Componente farmacêutico com base em hormÈnio da paratireóide humana e uma composição farmacêutica para administração intranasal compreendendo o componente
EP1391209A4 (en) * 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
EP1444263A4 (en) * 2001-11-05 2005-04-20 Lilly Co Eli METHOD FOR IMPROVING THE STABILITY OF A BONE BINDING IMPLANT
EP1767213A3 (en) * 2001-11-05 2007-04-25 Eli Lilly & Company Method for improving stability of a bone-connecting implant
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
WO2004087213A1 (en) 2003-04-02 2004-10-14 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
WO2004112826A1 (en) 2003-06-20 2004-12-29 Ares Trading Sa Freeze-dried fsh / lh formulations
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
US7329725B1 (en) 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
US7282493B2 (en) 2003-12-23 2007-10-16 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
EP1789075A4 (en) * 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
KR100700869B1 (ko) * 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Pth, 완충제 및 안정제를 포함하는 안정한 pth조성물
WO2007059470A2 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
DK2073789T3 (da) 2006-10-03 2019-08-05 Radius Health Inc Stabil sammensætning omfattende et knogle-anabolisk protein, nemlig en pthrp-analog, og anvendelser deraf
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP1958618A1 (de) 2007-02-15 2008-08-20 Octapharma AG Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren
BRPI0810835A2 (pt) * 2007-04-12 2015-06-16 Infinity Discovery Inc Formulações de hidroquinona ansamicina
US20080299228A1 (en) * 2007-05-29 2008-12-04 Alan Gerald Harris Topical compositions comprising a macromolecule and methods of using same
AU2008269086B2 (en) 2007-06-25 2014-06-12 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
EP2348845A4 (en) 2008-10-15 2013-01-23 Infinity Pharmaceuticals Inc ANSAMYCIN HYDROQUINONE COMPOSITIONS
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
ES2662018T3 (es) * 2009-09-09 2018-04-05 Asahi Kasei Pharma Corporation Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
PT3415139T (pt) 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
CN102731643A (zh) * 2012-06-26 2012-10-17 深圳翰宇药业股份有限公司 一种治疗骨质疏松多肽的制备方法
CN103301058A (zh) * 2013-06-17 2013-09-18 深圳翰宇药业股份有限公司 一种特立帕肽注射用组合物及其制备方法和制剂
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
CN106309358A (zh) * 2015-06-29 2017-01-11 成都金凯生物技术有限公司 含有人甲状旁腺激素的药物组合物及其制备方法与用途
JP6634758B2 (ja) * 2015-09-25 2020-01-22 ニプロ株式会社 液体組成物及び凍結乾燥製剤
SI3423103T1 (sl) 2016-03-01 2024-12-31 Ascendis Pharma Bone Diseases A/S Predzdravila PTH
HUE063235T2 (hu) 2016-09-29 2024-01-28 Ascendis Pharma Bone Diseases As Adagolási rendszer szabályozott leadású PTH vegyülethez
KR102611820B1 (ko) 2016-09-29 2023-12-07 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
JP7039574B2 (ja) 2016-09-29 2022-03-22 アセンディス ファーマ ボーン ディジージズ エー/エス 放出制御pth化合物の漸増用量設定
EP3565542B1 (en) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
JP2019060866A (ja) * 2017-09-22 2019-04-18 旭化成ファーマ株式会社 液状医薬組成物の体内動態を予測する方法
US20200289621A1 (en) * 2017-09-22 2020-09-17 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent stability
WO2019059303A1 (ja) 2017-09-22 2019-03-28 旭化成ファーマ株式会社 薬物動態及び/又は安全性に優れるテリパラチド含有液状医薬組成物
CN108159404B (zh) * 2018-01-05 2019-08-27 北京博康健基因科技有限公司 重组人甲状旁腺激素制剂及其制备方法
JP6510737B1 (ja) * 2018-05-17 2019-05-08 旭化成ファーマ株式会社 N−ホルミルピぺリジン含有量が低減されている、及び/又は、凍結乾燥ケーキの崩潰又は収縮が抑制されている、製剤
AU2020221491B2 (en) * 2019-02-11 2025-02-27 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of PTH conjugates
CN112439054B (zh) * 2019-08-28 2023-05-16 深圳翰宇药业股份有限公司 一种特立帕肽缓释凝胶注射液及其制备方法
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
WO2021195877A1 (en) * 2020-03-30 2021-10-07 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of human parathyroid hormone (pth) and methods for producing same
CA3221395A1 (en) 2021-06-10 2022-12-15 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients
CN113967249A (zh) * 2021-12-10 2022-01-25 深圳先进技术研究院 甲状旁腺激素在制备治疗男性抑郁症的药物或保健品中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JP2505812B2 (ja) * 1987-07-10 1996-06-12 旭化成工業株式会社 h―PTH(1―34)凍結乾燥組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
GB9020544D0 (en) † 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
IT1255723B (it) † 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
DE19538687A1 (de) † 1995-10-17 1997-04-24 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsformen enthaltend Parathormon

Also Published As

Publication number Publication date
EA200000629A1 (ru) 2000-12-25
TR200002134T2 (tr) 2000-11-21
IL136662A0 (en) 2001-06-14
ES2215268T3 (es) 2004-10-01
WO1999029337A1 (en) 1999-06-17
PT920873E (pt) 2004-06-30
ATE260113T1 (de) 2004-03-15
ZA9811127B (en) 2000-07-11
CZ20002115A3 (en) 2001-05-16
PE20000001A1 (es) 2000-01-17
EA004761B1 (ru) 2004-08-26
KR100482703B1 (ko) 2005-04-14
EP1417972B2 (en) 2018-08-22
CN1281370A (zh) 2001-01-24
CA2314313A1 (en) 1999-06-17
PL194268B1 (pl) 2007-05-31
TW570811B (en) 2004-01-11
DK1417972T3 (da) 2013-05-13
CA2314313C (en) 2005-02-08
DE69821872D1 (de) 2004-04-01
IL136662A (en) 2004-09-27
ES2405994T3 (es) 2013-06-04
EP0920873A2 (en) 1999-06-09
JP4405666B2 (ja) 2010-01-27
SK288203B6 (sk) 2014-07-02
UA72884C2 (uk) 2005-05-16
HU230784B1 (en) 2018-05-02
AR018526A1 (es) 2001-11-28
CY1114000T1 (el) 2016-07-27
MY120063A (en) 2005-08-30
NO20002945L (no) 2000-07-07
ES2405994T5 (es) 2019-01-30
EP1417972A1 (en) 2004-05-12
ID27741A (id) 2001-04-26
EP0920873B1 (en) 2004-02-25
AU1717799A (en) 2005-05-16
SK15322000A3 (sk) 2001-05-10
BR9813463A (pt) 2000-10-10
EP1417972B1 (en) 2013-04-10
EP0920873A3 (en) 1999-08-04
HUP0004447A2 (hu) 2001-04-28
JP2001525372A (ja) 2001-12-11
DK1417972T4 (da) 2018-10-22
CN1198644C (zh) 2005-04-27
PL340902A1 (en) 2001-03-12
AU759726B2 (en) 2003-04-17
NO20002945D0 (no) 2000-06-08
HK1021798A1 (en) 2000-07-07
PT1417972E (pt) 2013-05-24
HUP0004447A3 (en) 2003-06-30
DE69821872T2 (de) 2005-01-05
CZ302401B6 (cs) 2011-05-04
NZ505222A (en) 2003-05-30
EG23675A (en) 2007-04-15
KR20010032881A (ko) 2001-04-25
NO327302B1 (no) 2009-06-02

Similar Documents

Publication Publication Date Title
DK1417972T3 (da) Stabiliserede teriparatidopløsninger
NO20003131D0 (no) Krystallinsk teriparatid
DE69826749D1 (de) Stabilisierte Persäurelösungen
ID22500A (id) Turunan sulfonamida
ID24430A (id) Turunan-turunan benzamidina
NO2006014I1 (no) Insulin glulisin
ID24529A (id) Turunan-turunan 9-oksima eritromisin
DE59804393D1 (de) Luftleiteinrichtung
FI973171A0 (fi) Foerfarande foer drift av arbetsfartyg
NO20002555L (no) Skjøt
DE69815673D1 (de) Stabilisierte hydroxylaminlösungen
IT1304161B1 (it) Stiratoio
ID20897A (id) Susunan penutup-rapat
FI973588A0 (fi) Videodatasaendning
FI973961A0 (fi) Lyft- och belastningsanordning foer en valsstapel i en kalander
DE69734891D1 (de) Ausrichtvorrichtung
FI972138A0 (fi) Returtraog i bestrykningsanordning
FR2770103B1 (fr) Bigoudi perfectionne
ID21138A (id) Teknologi film-tipis untuk head-drum
KR980001295U (ko) 개량 도장
FI974242A0 (fi) Formframstaellning av plywoodprofil i kontinuerlig drift
BR7700789U (pt) Prumo
FI971123A0 (fi) Foervarings- och transportredskap i synnerhet foer pappersprodukter
FI971698A0 (fi) Klingstyrenhet i en cirkelsaog
FI972997A0 (fi) Anordning i en sugsamlarvagn